Mirum Pharmaceuticals (MIRM) Q1 2026 Call Results:
Management view
- “Based on this demand and the continued performance of all brands, we are raising our full-year revenue guidance to $660 million to $680 million.” (CEO and director Christopher Peetz)
- “IN
Alpha Search Disclaimer: This article was automatically generated by an AI tool from content available on Seeking Alpha and has not been curated or reviewed by humans. Due to the inherent limitations in the apply of AI-based tools, the accuracy, completeness or currency of such articles cannot be guaranteed. This article is for informational purposes only. Seeking Alpha does not take your goals or your financial situation into account and does not offer any personalized investment advice. Seeking Alpha is not a licensed securities dealer, broker-dealer, investment advisor or investment bank in the United States.
